ArticleImmunity2024
Cognate antigen engagement induces HIV-1 expression in latently infected CD4
Abstract read
In one paragraph
Article in Immunity, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- The Rectal Mucosal Myeloid Niche in HIV-1 Persistence: Reservoir Support, Viral Sequestration, and Therapeutic Opportunities.Viruses · 2026Review
- HCV-specific CD4EBioMedicine · 2026Article
- Antigen Stimulation Reactivates HIV-1 Proviruses Despite Integration in Repressive Chromatin.bioRxiv : the preprint server for biology · 2026Article
- Standardizing antiviral response metrics for mono- and combination therapies in acute, chronic and latent viral infections.Virology journal · 2026Review
- Article
- HIV-1 infection does not confer intrinsic resistance to cell death induced by cytotoxic T lymphocytes.bioRxiv : the preprint server for biology · 2026Article
- Dynamics of natural and pharmacologic control of an SIV variant with an envelope trafficking defect.The Journal of experimental medicine · 2026Article
- Persistent IFN-I signaling associated with the HIV-1 reservoir fuels immune exhaustion and reveals therapeutic targets.Frontiers in immunology · 2026Review
- Factors associated with resistance of HIV-1 reservoir viruses to neutralization by autologous IgG antibodies.The Journal of clinical investigation · 2025Article
- Clonal heterogeneity and antigenic stimulation shape persistence of the latent reservoir of HIV.PLoS computational biology · 2025Article
- Proviruses in CD4Science translational medicine · 2025Article
- Applications and limitations of the passenger hypothesis for HIV reservoir persistence and cure.Journal of virology · 2025Review
- FUBP3: A new player in HIV-1 transcriptional activation and immune regulation.Molecular therapy. Nucleic acids · 2025Article
- HIV-1 Rebound Virus Consists of a Small Number of Lineages That Entered the Reservoir Close to ART Initiation.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Milica MoskovljevicDepartment of Medicine, Division of Infectious Diseases, Johns Hopkins University, Baltimore, MD 21205, USA.
Filippo DragoniDepartment of Medicine, Division of Infectious Diseases, Johns Hopkins University, Baltimore, MD 21205, USA.
Nathan L BoardDepartment of Medicine, Division of Infectious Diseases, Johns Hopkins University, Baltimore, MD 21205, USA.
Fengting WuDepartment of Medicine, Division of Infectious Diseases, Johns Hopkins University, Baltimore, MD 21205, USA.
Jun LaiDepartment of Medicine, Division of Infectious Diseases, Johns Hopkins University, Baltimore, MD 21205, USA.
Hao ZhangDepartment of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.
James R WhiteResphera Biosciences, Baltimore, MD 21231, USA.
Rebecca HohDivision of HIV, School of Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.
Kenneth LynnPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Pablo TebasPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Karam MounzerJonathan Lax Treatment Center, Philadelphia FIGHT, Philadelphia, PA 19107, USA.
Steven G DeeksDivision of HIV, School of Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.
Luis J MontanerThe Wistar Institute, Philadelphia, PA 19104, USA.
Janet D SilicianoDepartment of Medicine, Division of Infectious Diseases, Johns Hopkins University, Baltimore, MD 21205, USA.
Robert F SilicianoDepartment of Medicine, Division of Infectious Diseases, Johns Hopkins University, Baltimore, MD 21205, USA; Howard Hughes Medical Institute, Baltimore, MD 21205, USA. Electronic address: rsiliciano1@jhmi.edu.
Francesco R SimonettiDepartment of Medicine, Division of Infectious Diseases, Johns Hopkins University, Baltimore, MD 21205, USA. Electronic address: fsimonetti@jhmi.edu.
Funding
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0MPediatric Adolescent Virus Elimination (PAVE) Martin Delaney CollaboratoryUM1AI164566 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Ann M Chahroudi, Deborah Persaud · 2021 to 2026
$35.5MBEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination ImmunotherapyUM1AI164570 · NIAID · WISTAR INSTITUTE · PI Luis J Montaner, James L. Riley · 2021 to 2026
$34.7MDelaney AIDS Research Enterprise to Cure HIVUM1AI164560 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS, Sharon Ruth Lewin · 2021 to 2026
$32.0MI4C 2.0: Immunotherapy for CureUM1AI164556 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Dan H. Barouch, John W Mellors · 2021 to 2026
$28.0MFirst-in-human study of two anti-SARS CoV-2 antibodies in health volunteersUM1AI126620 · NIAID · WISTAR INSTITUTE · PI MONTANER, LUIS J, RILEY, JAMES L. · 2016 to 2021
$24.5MInvestigating antigen-driven clonal proliferation to target HIV-1 persistenceDP5OD031834 · OD · JOHNS HOPKINS UNIVERSITY · PI SIMONETTI, FRANCESCO ROBERTO · 2021 to 2025
$2.0MHoward Hughes Medical InstituteNIAID NIH HHS P30 AI094189NIAID NIH HHS UM1 AI126620NIAID NIH HHS UM1 AI164556NIAID NIH HHS UM1 AI164560NIAID NIH HHS UM1 AI164566NIAID NIH HHS UM1 AI164570NIH HHS DP5 OD031834
Abstract
Despite antiretroviral therapy (ART), HIV-1 persists in latently infected CD4
Indexed as
CD4-Positive T-LymphocytesDendritic CellsHIV-1HIV InfectionsLymphocyte ActivationVirus LatencyAdultAntigens, ViralAnti-Retroviral AgentsCytomegalovirusFemalegag Gene Products, Human Immunodeficiency VirusGene Expression Regulation, ViralHumansMaleMiddle AgedAntigens, ViralAnti-Retroviral Agentsgag Gene Products, Human Immunodeficiency Virusantigenic stimulationCD4(+) T cellscytomegalovirusdendritic cellsHIV-1 latent reservoirHIV-1 persistencelatency reversal
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.